News
CHMP recommends Ozawade for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.- Bioproject Pharma
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozawade (pitolisant), intended for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.
The applicant for this medicinal product is Bioproject Pharma. The benefits of Ozawade are its ability to improve wakefulness in patients with obstructive sleep apnoea. The most common side effects are headache and insomnia..
Condition: Sleeping Disorders
Type: drug